Key result
Heart failure symptoms during AMI link to ~85% higher 1-year mortality in preserved LVEF.
Why the study?
Recent post-AMI trials of patients with LV dysfunction have shown low event rates, prompting evaluation of real-world post-AMI prevalence and outcomes stratified by LVEF and HF symptoms.
Does the presence of heart failure symptoms and reduced LVEF increase mortality in patients following acute myocardial infarction?
Cohort (n=70,809)
Yes
Does the presence of heart failure symptoms and reduced LVEF increase mortality in patients following acute myocardial infarction?
Heart failure symptoms during the index hospitalization for AMI significantly increase mortality risk, especially in patients with preserved LVEF, while reduced LVEF itself carries a high 1-year mortality up to 20% in real-world settings.
HF symptoms during AMI were associated with higher 1-year mortality, greatest in preserved LVEF; challenges LVEF-centric risk models and leaves open targeted strategies.
AIMS: Left ventricular (LV) dysfunction following acute myocardial infarction (AMI) is common even in the absence of signs and symptoms of heart failure (HF). Recent trials of patients with LV dysfunction post-AMI have demonstrated low event rates during follow-up. We aimed to assess the real-world prevalence and outcomes post-AMI, stratified by LV ejection fraction (LVEF) and the presence or absence of HF symptoms. METHODS AND RESULTS: Cohort study of patients with AMI registered in the Norwegian Myocardial Infarction Registry 2013-2022. Outcomes were short- and long-term all-cause mortality. Mortality was assessed by Kaplan-Meier survival curves, Life Table and multivariable Cox regression models. RESULTS: Among 70 809 AMI patients (mean age 68.1 ± 12.9 years, 31% female), preserved (≥50%), mildly reduced (41%-49%) and reduced (≤40%) LVEF were present in 63.5%, 23.2% and 13.3%, respectively. Symptomatic HF was present in 3.3%, 28.1% and 63.2% of patients with preserved, mildly reduced and reduced LVEF. For each LVEF category, 1-year cumulative mortality rate from discharge was 3.9%, 7.8% and 17.8% for asymptomatic, and 16.2%, 13.7% and 20.2% for symptomatic patients, respectively. Symptomatic patients discharged alive had higher risk of mortality than asymptomatic: adjusted hazard ratio 1.85 (1.70-2.02) for preserved LVEF, 1.33 (1.25-1.41) for mildly reduced LVEF and 1.15 (1.06-1.24) for reduced LVEF. CONCLUSIONS: Reduced LVEF in the acute phase of AMI was associated with up to 20% 1-year mortality after discharge, substantially higher than in recent post-MI trials. Symptoms of HF during the index hospitalization were associated with worse outcomes in patients with preserved LVEF but contributed little additive risk for patients with reduced LVEF.
No takes yet. Share an insight, caveat, or question.
Jortveit et al. (2025) conducted a cohort in Acute myocardial infarction (n=70,809). Symptomatic heart failure vs. Asymptomatic was evaluated on 1-year all-cause mortality (preserved LVEF subgroup) (HR 1.85, 95% CI 1.70-2.02). Heart failure symptoms during acute myocardial infarction increased 1-year mortality risk compared to asymptomatic patients, with the highest relative risk in preserved LVEF (HR 1.85; 95% CI 1.70-2.02).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: